...
首页> 外文期刊>Respiratory medicine >Variables associated with recovery from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease.
【24h】

Variables associated with recovery from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease.

机译:与慢性支气管炎和慢性阻塞性肺疾病急性加重期恢复相关的变量。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVE: To identify risk factors for late recovery and failure after ambulatory treatment of exacerbations of chronic bronchitis (CB) and chronic obstructive pulmonary disease (COPD). METHODS: Observational, non-randomised study of risk factors carried out in 2001 and 2002 in Primary Care practices. Patients aged 40 or older diagnosed with an exacerbation of CB or COPD of probable bacterial etiology were included in the study and followed up for 10 days. Patients were treated with amoxicillin plus clavulanic acid (co-amoxiclav) 500-125mg tds for 10 days, clarithromycin 500mg bd for 10 days or moxifloxacin 400mg od for 5 days. RESULTS: Two hundred and fifty-two general practitioners participated, registering 1147 valid patients. The rate of failure at day 10 was 15.1% without significant differences among the antibiotic treatments. Median time to recovery was 5 days. Factors significantly associated with late recovery (>5 days) on multivariate analysis were: use of long-term oxygen (OR=1.96; 95%CI=1.35-2.85); use of short-acting beta-2 agonists (OR=1.51; 1.17-1.92). The use of moxifloxacin had a "protective" effect against late recovery compared to co-amoxiclav (OR=0.34; 0.26-0.45) and clarithromycin (OR=0.41; 0.31-2.85). Factors associated with therapeutic failure were: previous hospitalisation (OR=1.61; 1.08-2.42); and 2 or more exacerbations the previous year (OR=1.51; 1.04-2.17); criteria of CB had a protective effect against failure (OR=0.53; 0.35-0.79). CONCLUSIONS: There are readily identifiable risk factors for ambulatory treatment failure of exacerbations of CB and COPD. In addition, long-term oxygen therapy and short-acting beta-2 agonists are associated with late recovery, and the use of moxifloxacin compared with co-amoxiclav and clarithromycin is associated with faster recovery of symptoms.
机译:目的:确定非卧床治疗慢性支气管炎(CB)和慢性阻塞性肺疾病(COPD)加重后的晚期恢复和衰竭的危险因素。方法:2001年和2002年在基层医疗实践中对危险因素进行了观察性,非随机性研究。被诊断患有CB或COPD病原菌可能加剧的40岁或40岁以上的患者纳入研究,并随访10天。患者接受阿莫西林加克拉维酸(co-amoxiclav)500-125mg tds治疗10天,克拉霉素500mg bd持续10天或莫西沙星400mg od治疗5天。结果:252名全科医生参加了该研究,登记了1147名有效患者。第10天的失败率为15.1%,抗生素治疗之间无显着差异。恢复时间中位数为5天。在多变量分析中与后期恢复(> 5天)显着相关的因素包括:长期氧气的使用(OR = 1.96; 95%CI = 1.35-2.85);使用短效β-2激动剂(OR = 1.51; 1.17-1.92)。与co-amoxiclav(OR = 0.34; 0.26-0.45)和克拉霉素(OR = 0.41; 0.31-2.85)相比,莫西沙星的使用对晚期恢复具有“保护性”作用。与治疗失败相关的因素有:先前住院(OR = 1.61; 1.08-2.42);前一年的病情加重2次或以上(OR = 1.51; 1.04-2.17); CB标准对失败具有保护作用(OR = 0.53; 0.35-0.79)。结论:CB和COPD急性加重的非卧床治疗失败有容易确定的危险因素。此外,长期的氧气疗法和短效的β-2激动剂与恢复较晚有关,与莫西沙星和克拉霉素相比,莫西沙星的使用可使症状恢复较快。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号